An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.

An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 2013 Jan 01; 19(1):279-90.

View in: PubMed

subject areas

Animals
Carcinoma, Non-Small-Cell Lung
Cell Line, Tumor
Cluster Analysis
Drug Resistance, Neoplasm
Epithelial-Mesenchymal Transition
ErbB Receptors
Gene Expression Profiling
Humans
Lung Neoplasms
Mice
Neoplasm Metastasis
Protein Kinase Inhibitors
Proteome
Proteomics
Proto-Oncogene Proteins
Receptor Protein-Tyrosine Kinases
Recurrence
Reproducibility of Results

authors with profiles

VARSHA V GANDHI
JIUN-KAE JACK LEE
GORDON B MILLS
LAUREN AVERETT BYERS
GEORGE R BLUMENSCHEIN
JING WANG
IGNACIO IVAN WISTUBA
JOHN VICTOR HEYMACH
JOHN N WEINSTEIN